Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.
The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects.
The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. CF101, Can-Fite`s lead drug candidate, is in advanced clinical development for the treatment of autoimmune-inflammatory diseases, including Rheumatoid Arthritis (RA) and Psoriasis. Can-Fite holds 82% in OphthaliX Inc. (OTCBB: OPLI) which develops CF101 for ophthalmic indications, including Dry Eye Syndrome, Glaucoma and Uveitis. CF102, Can-Fite`s second drug candidate, is being developed for the treatment of Hepatocellular Carcinoma (Primary Liver Cancer), under an Orphan Drug Status designated by the FDA. CF602 is Can-Fite’s second generation allosteric drug candidate for the treatment of inflammatory diseases, which has shown proof of concept in in vitro and in vivo studies. Can-Fite has a wealth of clinical experience which includes over 800 patients who have participated in clinical trials conducted by the company.
Can-Fite has licensed CF101 for the treatment of autoimmune diseases to Seikagaku Corporation (SKK) in Japan and for RA to Kwang Dong in Korea. Can-Fite is collaborating with leading researches from the US NIH and the Leiden University in the Netherlands.